A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2572 participants.

Also called NCT03066804

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,572 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03066804
  • EudraCT 2016-003410-28
Other papers using this trial's data
  • Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial JAMA, 2021-11-16 DOI, PubMed 34783839, PMC8596197 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Czechia, Denmark, Estonia, France, Germany, Guatemala, Hungary, India, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, Peru, Portugal, Romania, Russia, Serbia, Slovakia, Spain, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03066804. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-22 (actual); primary completion 2019-10-28 (actual). Results posted on 2021-02-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Acronym
PARALLAX
Intervention (Drug)
sacubitril/valsartan
Intervention (Drug)
Enalapril
Intervention (Drug)
Valsartan
Intervention (Drug)
Placebo to match sacubitril/valsartan
Intervention (Drug)
Placebo to match enalapril
Intervention (Drug)
Placebo to match valsartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03066804
Content hash
f94ccf9799aa3711e9a8b9ee77ac19243202ef59d83cf4e71998f7a5661b0ce6